HIGHLIGHTS
- who: License (https//creativecommons.org/licenses/by/ and colleagues from the Department of Medicine and Surgery, University of Parma, Parma, Italy have published the paper: A personalized molecular approach in multiple myeloma: the possible use of RAF/RAS/MEK/ERK and BCL-2 inhibitors, in the Journal: (JOURNAL)
- what: The authors focused on the possible effects in MM of off-label drugs that are currently used for other cancers with the same molecular characteristics. Preliminary results from this study showed an overall response rate (ORR) of 82% with 9 of 11 patients having at least . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.